Dexcom (NASDAQ:DXCM) was the target of a significant growth in short interest in March. As of March 29th, there was short interest totalling 14,147,733 shares, a growth of 17.6% from the March 15th total of 12,029,711 shares. Based on an average daily volume of 1,435,600 shares, the short-interest ratio is presently 9.9 days. Approximately 16.7% of the company’s stock are short sold.
Shares of NASDAQ:DXCM opened at $72.47 on Friday. Dexcom has a 12 month low of $42.62 and a 12 month high of $81.91. The company has a current ratio of 5.36, a quick ratio of 5.04 and a debt-to-equity ratio of 0.78.
Dexcom (NASDAQ:DXCM) last announced its earnings results on Tuesday, February 27th. The medical device company reported $0.10 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.03 by $0.07. The firm had revenue of $221.00 million for the quarter, compared to analysts’ expectations of $217.82 million. Dexcom had a negative return on equity of 13.99% and a negative net margin of 6.99%. analysts expect that Dexcom will post -0.56 earnings per share for the current fiscal year.
A number of institutional investors have recently bought and sold shares of DXCM. American International Group Inc. acquired a new position in Dexcom in the fourth quarter worth approximately $116,000. Thompson Davis & CO. Inc. acquired a new position in Dexcom in the fourth quarter worth approximately $137,000. Zions Bancorporation grew its position in Dexcom by 36,222.2% in the third quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock worth $160,000 after buying an additional 3,260 shares during the last quarter. Marco Investment Management LLC acquired a new position in Dexcom in the fourth quarter worth approximately $201,000. Finally, D.A. Davidson & CO. acquired a new position in Dexcom in the fourth quarter worth approximately $208,000.
A number of equities analysts have issued reports on DXCM shares. BidaskClub cut shares of Dexcom from a “buy” rating to a “hold” rating in a report on Tuesday, February 27th. Zacks Investment Research raised shares of Dexcom from a “sell” rating to a “hold” rating in a report on Friday, March 16th. Northcoast Research reissued a “buy” rating on shares of Dexcom in a report on Sunday, March 4th. Piper Jaffray set a $78.00 price target on Dexcom and gave the company a “buy” rating in a report on Friday, March 23rd. Finally, ValuEngine cut Dexcom from a “hold” rating to a “sell” rating in a report on Thursday, February 8th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $67.38.
Dexcom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Receive News & Ratings for Dexcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexcom and related companies with MarketBeat.com's FREE daily email newsletter.